Abstract:The use of existing mouse models in cancer research is of utmost importance as they aim to explore the casual link between candidate cancer genes and carcinogenesis as well as to provide models to develop and test new therapies. However, faster progress in translating mouse cancer model research into the clinic has been hampered due to the limitations of these models to better reflect the complexities of human tumors. Traditionally, immunocompetent and immunodeficient mice with syngeneic and xenografted tumors transplanted subcutaneously or orthotopically have been used. These models are still being widely employed for many different types of studies, in part due to their widespread availability and low cost. Other types of mouse models used in cancer research comprise transgenic mice in which oncogenes can be constitutively or conditionally expressed and tumor-suppressor genes silenced using conventional methods, such as retroviral infection, microinjection of DNA constructs, and the so-called "gene-targeted transgene" approach. These traditional transgenic models have been very important in studies of carcinogenesis and tumor pathogenesis, as well as in studies evaluating the development of resistance to therapy. Recently, the clustered regularly interspaced short palindromic repeats (CRISPR)-based genome editing approach has revolutionized the field of mouse cancer models and has had a profound and rapid impact on the development of more effective systems to study human cancers. The CRISPR/Cas9-based transgenic models have the capacity to engineer a wide spectrum of mutations found in human cancers and provide solutions to problems that were previously unsolvable. Recently, humanized mouse xenograft models that accept patient-derived xenografts and CD34+ cells were developed to better mimic tumor heterogeneity, the tumor microenvironment, and cross-talk between the tumor and stromal/immune cells. These features make them extremely valuable models for the evaluation of investigational cancer therapies, specifically new immunotherapies. Taken together, improvements in both the CRISPR/Cas9 system producing more valid mouse models and in the humanized mouse xenograft models resembling complex interactions between the tumor and its environment might represent one of the successful pathways to precise individualized cancer therapy, leading to improved cancer patient survival and quality of life.

Current Insights in Murine Models for Breast Cancer: Present, Past and Future

In vivo models in breast cancer research: progress, challenges and future directions

Emerging In Vitro and In Vivo Models: Hope for the Better Understanding of Cancer Progression and Treatment

Colorectal cancer murine models: Initiation to metastasis

Current views on in vivo models for breast cancer research and related drug development

Animal models for modeling pancreatic cancer and novel drug discovery

Translation Potential and Challenges of In Vitro and Murine Models in Cancer Clinic

Preclinical Cancer Models and Biomarkers for Drug Development: New Technologies and Emerging Tools

Mouse models of breast cancer in preclinical research

Trials, Tribulations, and Trends in Tumor Modeling in Mice

Models of breast cancer: quo vadis, animal modeling?

If you give a mouse a mutation: comparing the therapeutic utility of renowned mouse models of human cancers

Application of Animal Models in Cancer Research: Recent Progress and Future Prospects

The past, present, and future of breast cancer models for nanomedicine development

Abstract A062: Somatic engineering of rat models to recapitulate human breast cancer evolution and heterogeneity

Experimental mouse models for translational human cancer research

Transgenic Mouse Models in Cancer Research

Preclinical Molecular Imaging for Precision Medicine in Breast Cancer Mouse Models

Orthotopic and metastatic tumour models in preclinical cancer research

Humanized Mouse Models for Immuno-oncology Drug Discovery

Insights from transgenic mouse models of PyMT-induced breast cancer: recapitulating human breast cancer progression in vivo